ArticlePharmacoEconomics2026
Informing the Equitable Implementation of Hepatitis C Interventions: Cost-Effectiveness Modeling in Rural Populations of People Who Inject Drugs.
Article in PharmacoEconomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study evaluates the cost effectiveness of implementing evidence-based interventions among persons who inject drugs (PWID) in rural settings, where structural barriers and limited resources contribute to disproportionate hepatitis C virus (HCV) burden. Findings are intended to guide equitable implementation planning and resource allocation.
methodsWe developed an economic-epidemiological model to describe HCV transmission among PWID to assess the cost effectiveness of testing, treatment, and harm reduction interventions over a 20-year time horizon. Outcomes included healthcare costs, disability-adjusted life years (DALYs), and incremental cost-effectiveness ratios (ICERs).
resultsExpanding testing and treatment was highly cost effective (US$1139 per DALY averted), achieved a 90% reduction in HCV incidence by 2035 (within 10 years of the modeled horizon), and averted 45,126 HCV infections equivalent to protecting one in four people at risk of HCV infection over 20 years. Adding syringe services programs (SSPs, 25% coverage) accelerated incidence reduction and remained cost effective (US$2116 per DALY averted). Adding medication-assisted treatment (MAT, 25% coverage) was more costly (US$12,545 per DALY averted) and prevented fewer infections than when adding SSPs. Combining expanded testing and treatment with both MAT and SSPs averted 53,503 HCV infections, protecting one in three people at risk and achieved a 90% incidence reduction in 6 years for US$14,350 per DALY averted.
conclusionsScaling up testing and treatment is a highly cost-effective strategy for rural communities disproportionately affected by HCV. Adding SSPs enhances value and offers an approach to guide policy decisions to reduce disparities where harm reduction infrastructure is limited. Investment in comprehensive, community-centered interventions is essential to advance health equity in HCV elimination efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.